Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,044,811
  • Shares Outstanding, K 117,597
  • Annual Sales, $ 1,015 M
  • Annual Income, $ 444,090 K
  • EBIT $ 808 M
  • EBITDA $ 886 M
  • 60-Month Beta 0.95
  • Price/Sales 7.92
  • Price/Cash Flow 14.69
  • Price/Book 15.95

Options Overview Details

View History
  • Implied Volatility 39.37% (-1.52%)
  • Historical Volatility 31.44%
  • IV Percentile 66%
  • IV Rank 33.54%
  • IV High 59.09% on 04/04/25
  • IV Low 29.41% on 06/16/25
  • Expected Move (DTE 22) 8.76 (12.80%)
  • Put/Call Vol Ratio 0.60
  • Today's Volume 141
  • Volume Avg (30-Day) 598
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 11,148
  • Open Int (30-Day) 17,614
  • Expected Range 59.66 to 77.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.84
  • Number of Estimates 4
  • High Estimate 1.95
  • Low Estimate 1.74
  • Prior Year 1.19
  • Growth Rate Est. (year over year) +54.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
61.22 +11.74%
on 12/11/25
74.25 -7.87%
on 11/26/25
-5.59 (-7.55%)
since 11/24/25
3-Month
61.22 +11.74%
on 12/11/25
76.30 -10.34%
on 10/01/25
-7.23 (-9.56%)
since 09/24/25
52-Week
46.99 +45.57%
on 12/26/24
79.50 -13.95%
on 09/23/25
+20.87 (+43.90%)
since 12/24/24

Most Recent Stories

More News
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

RYBREVANT FASPRO ™ is approved across all indications of RYBREVANT® (amivantamab-vmjw)

HALO : 68.41 (+0.07%)
Jim Lang Elected to Halozyme's Board of Directors

SAN DIEGO , Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:  HALO ) ("Halozyme") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings...

HALO : 68.41 (+0.07%)
Stocks Settle Mixed on Higher Bond Yields

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up by +0.11%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down by -0.07%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.10%....

PATH : 17.16 (+7.52%)
DG : 135.45 (+0.89%)
HRL : 24.35 (+1.08%)
TXN : 177.13 (+0.03%)
$IUXX : 25,656.15 (+0.27%)
SAIC : 102.80 (+0.14%)
ASML : 1,065.52 (+0.35%)
ZNH26 : 112-165s (+0.19%)
COST : 871.86 (+2.00%)
FIVE : 188.67 (+0.46%)
ESH26 : 6,982.50s (+0.31%)
GFS : 35.75 (-0.11%)
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

SAN DIEGO , Dec. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering...

HALO : 68.41 (+0.07%)
Stocks Pressured as Bond Yields Rise and Chip Stocks Fall

The S&P 500 Index ($SPX ) (SPY ) is down by -0.06%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.28%. December E-mini S&P futures...

PATH : 17.16 (+7.52%)
DG : 135.45 (+0.89%)
HRL : 24.35 (+1.08%)
BF.B : 26.89 (+0.94%)
$IUXX : 25,656.15 (+0.27%)
SAIC : 102.80 (+0.14%)
ASML : 1,065.52 (+0.35%)
ZNH26 : 112-165s (+0.19%)
COST : 871.86 (+2.00%)
ESH26 : 6,982.50s (+0.31%)
GFS : 35.75 (-0.11%)
LRCX : 177.33 (+1.24%)
Stocks Pressured by Higher Bond Yields and Chip Stock Weakness

The S&P 500 Index ($SPX ) (SPY ) is down up by -0.06%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.38%. December E-mini S&P...

MSTR : 158.71 (+0.53%)
PATH : 17.16 (+7.52%)
DG : 135.45 (+0.89%)
HRL : 24.35 (+1.08%)
GLXY : 24.43 (-0.65%)
BF.B : 26.89 (+0.94%)
$IUXX : 25,656.15 (+0.27%)
COIN : 239.73 (-1.06%)
ASML : 1,065.52 (+0.35%)
ZNH26 : 112-165s (+0.19%)
FIVE : 188.67 (+0.46%)
ESH26 : 6,982.50s (+0.31%)
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host...

HALO : 68.41 (+0.07%)
Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

Royalty revenue contribution expected to begin as early as 2030

HALO : 68.41 (+0.07%)
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

SAN DIEGO and UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Nov. 17, 2025 /PRNewswire/ -- Merus N.V.  (Nasdaq: MRUS) ("Merus"), an oncology company developing innovative, full-length multispecific...

MRUS : 96.91 (+0.01%)
HALO : 68.41 (+0.07%)
FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology

HALO : 68.41 (+0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company...

See More

Key Turning Points

3rd Resistance Point 69.54
2nd Resistance Point 69.27
1st Resistance Point 68.84
Last Price 68.41
1st Support Level 68.15
2nd Support Level 67.88
3rd Support Level 67.45

See More

52-Week High 79.50
Last Price 68.41
Fibonacci 61.8% 67.08
Fibonacci 50% 63.25
Fibonacci 38.2% 59.41
52-Week Low 46.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar